Litcius/Paper detail

Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective Platinum<sup>IV</sup> Prodrug Against Triple Negative Breast Cancer

Muhammad Nafees, Tan Cai‐Ping, Sadia Nasreen, Zong‐Wan Mao

2021Chemistry - An Asian Journal12 citationsDOI

Abstract

Abstract A mitochondria targeting dual‐action platinum IV prodrug exhibits high anticancer activity in triple negative breast cancer cells. The complex intervenes in several cellular processes including DNA damage, perturbation of mitochondrial bioenergetics and induction of necrosis to kill cancer cells.

Topics & Concepts

Triple-negative breast cancerProdrugCisplatinDoxorubicinMitochondrionCancer researchBreast cancerChemistryCancer cellPlatinumDNA damageApoptosisCancerChemotherapyBiologyMedicineBiochemistryDNAInternal medicineCatalysisMetal complexes synthesis and propertiesDrug Transport and Resistance MechanismsMolecular Sensors and Ion Detection
Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective Platinum<sup>IV</sup> Prodrug Against Triple Negative Breast Cancer | Litcius